Lineage Cell Therapeutics stock rises on positive 36-month OpRegen data

Published 23/06/2025, 13:50
© Reuters.

Investing.com -- Lineage Cell Therapeutics Inc (NYSE American:NYSE:LCTX) stock rose 2.7% after the company announced positive 36-month results from a Phase 1/2a clinical study of its RG6501 (OpRegen) cell therapy for geographic atrophy secondary to age-related macular degeneration.

The data, presented at Clinical Trials at the Summit 2025, showed that patients who received OpRegen maintained improvements in vision and retinal structure for at least three years following a single administration. Patients in Cohort 4, who had less advanced disease, demonstrated a mean improvement of 6.2 letters in Best Corrected Visual Acuity (BCVA) at the 36-month mark, compared to 5.5 letters at 24 months.

Results were particularly promising in the five patients who received extensive OpRegen coverage across their geographic atrophy areas, with these patients showing a mean BCVA improvement of 9.0 letters at 36 months, up from 7.4 letters at 24 months.

"Long term clinical outcomes following a single administration of OpRegen cell therapy is challenging the long-held view that GA causes irreversible damage," stated Brian M. Culley, Lineage CEO. "Among patients who received fulsome coverage by OpRegen cell therapy, anatomical and functional benefits from a single administration have lasted for at least three years."

The therapy also demonstrated sustained improvements in retinal structure through 36 months, with treated eyes maintaining improvements in the retinal pigment epithelium drusen complex area (+1.9 mm²) while untreated fellow eyes showed deterioration (-3.8 mm²).

RG6501 is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech. The therapy is currently being evaluated in a Phase 2a "GAlette study" that is testing proprietary surgical devices for improved subretinal delivery of the cell therapy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.